ANI Pharmaceuticals Inc
NASDAQ:ANIP

Watchlist Manager
ANI Pharmaceuticals Inc Logo
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Watchlist
Price: 57.86 USD -1.33%
Market Cap: 1.2B USD
Have any thoughts about
ANI Pharmaceuticals Inc?
Write Note

ANI Pharmaceuticals Inc
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ANI Pharmaceuticals Inc
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Other Current Liabilities
$38.4m
CAGR 3-Years
6%
CAGR 5-Years
19%
CAGR 10-Years
41%
Johnson & Johnson
NYSE:JNJ
Other Current Liabilities
$4.8B
CAGR 3-Years
31%
CAGR 5-Years
10%
CAGR 10-Years
12%
Bristol-Myers Squibb Co
NYSE:BMY
Other Current Liabilities
$4.8B
CAGR 3-Years
9%
CAGR 5-Years
24%
CAGR 10-Years
9%
Pfizer Inc
NYSE:PFE
Other Current Liabilities
$24.2B
CAGR 3-Years
-8%
CAGR 5-Years
12%
CAGR 10-Years
10%
Merck & Co Inc
NYSE:MRK
Other Current Liabilities
$7.2B
CAGR 3-Years
40%
CAGR 5-Years
24%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Other Current Liabilities
$5.6B
CAGR 3-Years
30%
CAGR 5-Years
21%
CAGR 10-Years
5%
No Stocks Found

ANI Pharmaceuticals Inc
Glance View

Market Cap
1.2B USD
Industry
Pharmaceuticals

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 601 full-time employees. The company went IPO on 2000-05-04. The firm is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The firm focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. The Company’s products include both branded and generic pharmaceuticals. Its generic products include Aspirin and Extended Release Dipyridamole, Bretylium Tosylate Injection USP, cholestyramine, Etodolac, Fluvoxamine, Indapamide, Nilutamide, Vancomycin and more. Its branded products include Arimidex (anastrozole) tablets, Atacand HCT Tablets, Atacand (candesartan cilexetil) Tablets, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan and Vancocin. The company operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.

ANIP Intrinsic Value
96.33 USD
Undervaluation 40%
Intrinsic Value
Price

See Also

What is ANI Pharmaceuticals Inc's Other Current Liabilities?
Other Current Liabilities
38.4m USD

Based on the financial report for Sep 30, 2024, ANI Pharmaceuticals Inc's Other Current Liabilities amounts to 38.4m USD.

What is ANI Pharmaceuticals Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
41%

Over the last year, the Other Current Liabilities growth was -32%. The average annual Other Current Liabilities growth rates for ANI Pharmaceuticals Inc have been 6% over the past three years , 19% over the past five years , and 41% over the past ten years .

Back to Top